HRMY News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

HR

Mkt Cap

$2.21B

Volume

740.20K

Next Earnings

November 3rd

Loading chart

HR

HRMYHarmony Biosciences Holdings, Inc. Common Stock

HRMY

Pay with—

Available Balance0.00

HR

Mkt Cap

$2.21B

Volume

740.20K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds.Zacks Investment Research · Oct 16, 2026

Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsightOver 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.GlobeNewswire Inc. · Oct 13, 2026

Why Harmony Biosciences Stock Got Mashed on MondayHarmony Biosciences stock fell over 5% on Monday following the announcement of a planned CEO succession. Current COO Peter Anastasiou will replace CEO Jeffrey Dayno effective January 1, 2027, in a planned transition. Despite the company maintaining its strategic priorities and reiterating full-year Wakix revenue guidance of $1-$1.04 billion, investors reacted negatively to the leadership change. The analyst suggests this may present a buying opportunity at a discount.The Motley Fool · Oct 12, 2026

Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of GrowthHarmony Biosciences announced that Peter Anastasiou, current Sr. EVP and COO, will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno who will retire after nine years. The company reiterates its full-year 2026 WAKIX net revenue guidance of $1.0-1.04 billion and remains on track to report BP-205 MAD study data in Q4 2026.GlobeNewswire Inc. · Oct 12, 2026

HRMY vs. CSLLY: Which Stock Is the Better Value Option?In a comparison of two medical-biomedical stocks, Harmony Biosciences Holdings (HRMY) emerges as the superior value option compared to CSL Limited Sponsored ADR (CSLLY). HRMY has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 10.52, and a Value grade of A. CSLLY has a Zacks Rank of #4 (Sell) with a forward P/E of 19.66 and a Value grade of C, making it less attractive to value investors.Zacks Investment Research · Oct 6, 2026

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?Harmony Biosciences (HRMY) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating and an A grade for Value. The stock trades at a P/B ratio of 2.42, P/S ratio of 2.42, and P/CF ratio of 9.34, all favorable compared to industry averages, suggesting the company may be undervalued in the market.Zacks Investment Research · Oct 6, 2026

A beaten-down biotech just lost a meaningful backer — should you care?Bridge City Capital fully exited its position in Harmony Biosciences Holdings, selling all 237,103 shares worth approximately $7.77 million during Q1 2026. The stake, which represented 2.6% of the fund's AUM in the prior quarter, was completely liquidated. Harmony Biosciences, a rare neurological disorder treatment developer, has underperformed the S&P 500 by 42.07 percentage points over the past year.The Motley Fool · May 19, 2026

12 Small-Cap Stocks Primed for Breakouts as Earnings ApproachThe Russell 2000 small-cap index has outperformed major indices, rising 8.40% in the past month. With Q1 2026 earnings season underway, analysts expect small-cap earnings growth of 18.4% compared to 9.8% for S&P 500 companies. The article highlights three undervalued small-cap stocks with significant upside potential: Goosehead Insurance (technology-driven insurance broker), EverCommerce (SaaS platform for service businesses), and Harmony Biosciences (rare disease biopharmaceutical company).Investing.com · Apr 16, 2026

Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800Harmony Biosciences' CFO Sandip Kapadia sold all 20,961 of her directly held shares for approximately $752,800 on January 15, 2026, fully exiting her equity position. The sale was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider exit, the company reported strong Q3 2025 earnings and expects to generate over $1 billion in revenue from its flagship product WAKIX by end of 2026.The Motley Fool · Feb 1, 2026

Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?Harmony Biosciences has achieved remarkable financial success with its narcolepsy drug Wakix, growing sales at 40% CAGR to nearly $870 million and achieving profitability with $186 million in net income. However, the stock has remained flat since its IPO due to concerns including a 2023 short-seller report alleging fraud, pending patent expiration in 2030, and intense competition from Jazz Pharmaceuticals' blockbuster treatments Xywav and Xyrem.The Motley Fool · Jan 27, 2026

to start trading

HR

HRMYHarmony Biosciences Holdings, Inc. Common Stock

HRMY

Pay with—

Available Balance0.00

Your PositionYou don't own any HRMY yet.

Related Tickers

Earnings